Combined immunotherapy and radiation for colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests the combination of two immunotherapy drugs (botensilimab and balstilimab) plus targeted radiation to liver tumors. It's for people with colorectal cancer that has spread and hasn't responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that has spread to the liver and at least one other spot outside the liver
- Your cancer is mismatch repair stable (MSS) or has normal MMR function
- You've tried or can't take 5-FU, oxaliplatin, and irinotecan
- You're 18 or older and in fairly good health (ECOG 0 or 1)
- You have no active autoimmune disease or serious bowel obstruction
- You're not pregnant and agree to use effective birth control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs for patients with colorectal cancer that has spread to the liver. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests combinations of immunotherapy drugs for people with colorectal cancer that has spread to the liver and is scheduled for surgery. The goal is to see if these treatments are safe and effective before and after the operation.
This trial combines targeted radiation (SBRT) with an immunotherapy drug (PD-1 inhibitor) to treat colorectal cancer that has spread to the liver and can't be removed by surgery. It aims to help shrink or control tumors in patients whose cancer has a normal DNA repair system (pMMR/MSS).
This trial tests combining focused radiation (SBRT) with immunotherapy for colorectal cancer that has spread to the liver or lungs. The goal is to see if this combination can shrink tumors and improve control of the cancer.
This trial combines a special type of radiation, immunotherapy, a targeted blood-vessel drug, and a chemotherapy pill for patients whose colorectal cancer has continued to grow after two prior treatments. The hope is that this combination can shrink tumors or slow down the cancer better than current options.
This trial tests a combination of two immunotherapy drugs to see if they can stop colorectal cancer from returning after standard treatment. It is for people who still have cancer DNA in their blood after surgery and/or chemotherapy, which means they are at high risk of the cancer coming back.
Hear when a new Non-MSI-H or pMMR Colorectal Cancer With Liver Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.